UK Competition Watchdog Targets Four Firms Over Seven-Fold Prochlorperazine Price Hike
Executive Summary
The UK CMA alleges that four companies were involved in a non-compete agreement that resulted in a 700% increase in the cost to the NHS of a generic medicine for nausea and dizziness.
You may also be interested in...
UK Competition Body Steps Up Generic Hydrocortisone Probe
Two generics firms have been provisionally found to have breached competition law by reaching agreements intended to delay the entry of competing products.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.